Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
Public ClinicalTrials.gov record NCT04039347. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Extension Clinical Trial to Demonstrate Efficacy and Safety of Liposomal Cyclosprine A Via the PARI Investigational eFlow® Device and SoC in Treating Bronchiolitis Obliterans in Patients Post Single or Double Lung Transplant
Study identification
- NCT ID
- NCT04039347
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Zambon SpA
- Industry
- Enrollment
- 164 participants
Conditions and interventions
Interventions
- Liposomal Cyclosporine A 10 mg Drug
- Liposomal Cyclosporine A 5 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 11, 2020
- Primary completion
- Feb 24, 2026
- Completion
- Feb 24, 2026
- Last update posted
- Apr 6, 2026
2020 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner - University Medical Center | Phoenix | Arizona | 85006 | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90095 | — |
| UCSF | San Francisco | California | 94143 | — |
| UCSF Center for Advanced Lung Disease | Stanford | California | 94305 | — |
| University of Florida Dept of Pulmonary Medicine | Gainesville | Florida | 32610 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| UK Albert B. Chandler Hospital | Lexington | Kentucky | 40508 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Johns Hopkins University Hospital | Baltimore | Maryland | 21287 | — |
| Barnes-Jewish Hospital | St Louis | Missouri | 63110 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| OSU Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Temple University Hospital | Philadelphia | Pennsylvania | 19140 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04039347, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04039347 live on ClinicalTrials.gov.